How we run ourselves
The Royal Marsden is managed by a Board of Directors made up of a Chairman, Chief Executive, four Executive Directors and six non-Executive Directors
The Board is satisfied that its current composition and balance between skills, knowledge and experience is complete and appropriate to the requirements of the Trust.
The day-to-day running of the hospital is carried out by the Leadership Team made up of the Chief Executive, four Executive Directors, and the other members listed below.
Board meeting papers can be downloaded below. Please contact the Corporate Governance office on 020 7811 8239 or email Corporate.Governance@rmh.nhs.uk if you would like to request previous meeting papers.
Mr Charles Alexander
Charles Alexander was appointed as Chairman in December 2016. His private sector career spanned 25 years at Rothschild, and 10 at General Electric. His Board experience includes directorships of quoted companies in London, New York, Paris, Luxembourg, Istanbul and Santiago, as well as in the third sector. He was a Non-Executive Director of the Department of Culture, Media and Sport (until April 2021), and chairs The Countess of Munster Musical Trust as well as the musical charity Opera Rara. Charles Alexander currently also serves as Chairman of the Board of Trustees of The Royal Marsden Cancer Charity.
Dame Cally Palmer
Dame Cally Palmer became Chief Executive of The Royal Marsden in 1998. She is also a Trustee of the ICR and a Trustee of The Royal Marsden Cancer Charity. She holds an MSc in Management from the London Business School, which she gained with distinction in 1995, and is a member of the Institute of Health Services Management. Dame Cally was appointed as National Cancer Director for NHS England in 2015 and holds this position alongside her role as Chief Executive of The Royal Marsden. Dame Cally was awarded a DBE in 2020 for her contribution to cancer medicine.
Mr Karl Munslow Ong
Chief Operating Officer
Karl Munslow Ong joined The Royal Marsden in November 2018 as the Chief Operating Officer. Before taking on the role, Karl was the Deputy Chief Executive at Chelsea and Westminster NHS Foundation Trust, having joined as their Chief Operating Officer in March 2015, also working with The Royal Marsden through the Fulham Road Collaborative, Sphere and RM Partners. Karl started his career as a management consultant for PricewaterhouseCoopers, before moving to work at a strategic health authority. He was previously Chief Operating Officer at Hillingdon Hospital and has extensive operational management experience across a number of other acute trusts in London.
Dr Nicholas van As
Dr Nicholas van As was appointed Medical Director in January 2016. He has been a Consultant Clinical Oncologist in the Urology Unit at The Royal Marsden since 2008 and is the hospital’s Clinical Lead for stereotactic body radiotherapy (SBRT) and CyberKnife. Dr van As is also Chair of the UK SBRT Consortium and the national clinical lead for NHS England’s Commissioning through Evaluation Programme for SBRT. His main research interests are in stereotactic and image-guided radiotherapy, risk prediction in early prostate cancer, and functional MRI, and he has published numerous papers on these subjects and delivered presentations at international meetings. He is the Chief Investigator for the PACE trial – an international, randomised controlled trial comparing SBRT to image-guided radiotherapy (IGRT) and surgery for treating prostate cancer.
Miss Mairead Griffin
Mairead Griffin is an experienced cancer clinician by background and has held a series of senior clinical leadership roles, including Deputy Chief Nurse and Director of Nursing for Cancer and Surgery. She is currently The Chief Nurse at The Royal Marsden NHS Foundation Trust. She is passionate about the delivery of high-quality care for all service users and has developed strong system leadership skills, including developing the personalised care agenda. Staff engagement and support is key to the delivery of safe and effective care and is one of her main priorities.
Mr Marcus Thorman
Chief Financial Officer
Marcus Thorman joined The Royal Marsden as Chief Financial Officer in January 2015 from Imperial College Healthcare NHS Trust. Since joining the NHS through the graduate financial management training scheme, he has worked in several provider trusts including mental health and community, acute, teaching and specialist. Marcus has been involved in merging two trusts, private finance initiative (PFI) schemes and running a financial shared service for a number of NHS organisations. At Kettering General Hospital he was Deputy Director of Finance before taking on his first role as a Finance Director overseeing the process for delivering foundation trust status in 2008. During his time at Imperial College Healthcare NHS Trust, he led the finance team in delivering one of the largest financial turnarounds in the NHS; taking the Trust from a planned deficit to a surplus in two financial years. For seven months he was acting Chief Financial Officer while a new Chief Executive was being appointed.
Mr Ian Farmer*
Ian Farmer joined The Royal Marsden as a Non-Executive Director and Chair of the Audit and Finance Committee on 1 April 2014. Ian is a Chartered Accountant, Non-Executive Chairman of South Harz Potash Ltd and former Chief Executive Officer of Lonmin Plc.
Professor Paul Workman PhD DSc FMedSci FRSC
Professor Paul Workman joined The Royal Marsden as a Non-Executive Director on 1 July 2014 in his capacity as ex officio Chief Executive and President of the Institute of Cancer Research (ICR) in London. He is also Harrap Professor of Pharmacology at the ICR and was previously Head of the ICR’s Division of Cancer Therapeutics and Director of its Cancer Research UK (CRUK) Cancer Therapeutics Unit. He was Founding Director of the CRUK ICR/Imperial Convergence Science Centre. Professor Workman has 40 years of experience in cancer research, including periods at Cambridge University (MRC Clinical Oncology Unit), Glasgow University (CRC/CRUK Beaton Laboratories) and AstraZeneca. He is internationally recognised for research in cancer drug discovery and chemical biology, and has been instrumental in the discovery of more than 20 drug candidates. Honours including election as a Fellow of the Royal Society and Fellow of the Academy of Medical Sciences. He was a scientific co-founder of Piramed Pharma and Chroma Therapeutics, serves as a Non-Executive Director of STORM Therapeutics, and is the Executive Director of the non-profit Chemical Probes Portal.
Mr Mark Aedy*
Senior Independent Director
Mark Aedy joined The Royal Marsden as a Non-Executive Director in April 2016. He has 40 years’ experience in the financial services sector, building and managing investment banking franchises in the UK and internationally. At present, he is a Managing Director and Head of EMEA and Asia Investment Banking at Moelis & Company, a global independent investment bank, and is on its management committee. Prior to Moelis & Company, he worked at Bank of America Merrill Lynch serving on the Global Corporate and Investment Banking Executive Committee and at Merrill Lynch, where he was Head of Investment Banking, EMEA. He is a Trustee of The HALO Trust.
Ms Heather Lawrence OBE*
Heather Lawrence is an accomplished former chief executive with a track record of service quality improvement. She joined The Royal Marsden as a Non-Executive Director in July 2017. Her last chief executive position was at Chelsea and Westminster NHS Foundation Trust from 2000 to 2012. Since 2012, she has held a number of non-executive positions and currently serves as Non-Executive Chair of the London Ambulance Service, is a Trustee of NHS Providers and a Trustee of the British Renal Society. She is a nurse, teacher and HR professional by background, with an impressive track record of success in both her executive and non-executive roles. She brings her patient-focused clinical expertise to the role of the Non-Executive Director.
Professor Martin Elliott*
Professor Elliott recently finished a career as a paediatric cardiothoracic surgeon, spent largely at Great Ormond Street Hospital for Children, where he held several clinical leadership positions including Co-Medical Director from 2010 to 2015, specialising in quality and safety, digital technology and clinical outcomes. He holds a Chair in Cardiothoracic Surgery at University College London and is Fellow and Emeritus Professor of Physics at Gresham College. He is also a Non-Executive Director of Children’s Health Ireland. As an established clinical leader and researcher, he brings a strong understanding of the particular challenges and opportunities facing specialist trusts.
Mr William Jackson*
William Jackson is the Chief Executive of Bridgepoint. Bridgepoint provides capital for growth companies through its Bridgepoint Europe, Bridgepoint Development Capital, Bridgepoint Growth and Bridgepoint Credit funds. The firm has currently €26 billion under management and executes its strategies using a multinational team of investment professionals and operating executives located in offices in Europe, Shanghai, New York and San Francisco. William, a graduate of Oxford University, is one of the firm’s founders and has led the business since 2001. William is also currently President of the Board of Dorna Sports, the international sports management company which runs the MotoGP World Motorcycling Championship, and a Non-Executive Director of Berkeley Group plc, the FTSE 100 property company. He is also a Governor of Wellington College.
Mr Christopher Clark*
Chris Clark is a Non-Executive Director of the Aviva Insurance Limited (AIL) Board and Chairman of Aviva’s UKD digital legal entity. He also chairs both the Aviva AIL and UKD Conduct Committees. He is an adviser to a number of private equity houses specialising in marketing services. In his corporate career, Chris was at HSBC between 2001 and 2017, and was Global Head of Marketing between 2010 and 2017, reporting to the Group Chief Executive Officer. He was a member of the HSBC Group Management Board and Group Risk Management Committee. Prior to HSBC, Chris spent his career in the advertising and marketing services business, with time at Saatchi and Saatchi and a four-year period in New York.
*The Non-Executive Directors which the Board considers to be independent.
Member of Remuneration Committee
Member of Audit and Finance Committee
Member of Quality, Assurance and Risk Committee
Member of the Board of Trustees of The Institute of Cancer Research
Other members of the Leadership Team
Pictured (left to right):
1st row: Dame Cally Palmer, Chief Executive, Karl Munslow Ong, Chief Operating Officer, Dr Nicholas van As, Medical Director, Mairead Griffin, Chief Nurse, Marcus Thorman, Chief Financial Officer, Krystyna Ruszkiewicz, Director of Workforce, Shams Maladwala, Managing Director of Private Care, Professor David Cunningham, Director of Clinical Research, Professor David Nicol, Chief of Surgery
2nd row: Dr Susan Lalondrelle, Lead for Clinical Oncology, Susan Sinclair, Managing Director of RM Partners, Lisa Emery, Chief Information Officer, Antonia Dalmahoy, Managing Director of The Royal Marsden Cancer Charity, Rachael Reeve, Director of Marketing and Communications, Nicky Browne, Director of Transformation and Charity Liaison, Professor Stephen Johnston, Head of Medical Oncology, Steven Francis, Director of Performance and Information
3rd row: Ellie Bateman, Divisional Director, Cancer Services, Sunil Vyas, Director of Projects and Estates, Dr Gary Wares, Divisional Medical Director of Clinical Services, Dr Jayne Wood, Divisional Medical Director of Cancer Services, Mr Thomas Ind, Divisional Medical Director, Private Care
Board and Leadership Team Register of Interests
Leadership Team Register of Interests April 2021.xlsx
Size: 22.3KB Published Date: April 2021
Board of Directors Register of Interests Feb 2021.xlsx